Loading
Life sciences · Journal article
Targets · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Hidradenitis suppurativa (HS) is a systemic inflammatory skin disease associated with obesity, insulin resistance, and visceral adiposity. Chronic metainflammation may contribute to cutaneous disease activity, while metabolic dysregulation potentially occurs independently of body mass index (BMI). Additionally, emerging metabolic pharmacotherapies may provide weight-dependent and weight-independent immunomodulatory benefits in HS. This narrative review synthesizes clinical and mechanistic evidence for glucagon-like peptide-1 receptor agonists (GLP-1RAs), GLP-1RA multi-agonists, metformin, sodium–glucose cotransporter 2 inhibitors (SGLT-2is), and peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists in HS management. A structured PubMed and Embase search (28 March 2026) identified key metabolic–inflammatory targets. Proposed mechanisms include adipokine axis modulation (increased adiponectin; reduced leptin, retinol-binding protein 4, and haptoglobin); inhibition of nuclear factor kappa B (NF-κB) and NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) inflammasome signaling; restoration of cutaneous antimicrobial peptides; and improved gut barrier function. Early screening for metabolic syndrome (MetS) enables dermatologists to initiate targeted metabolic pharmacotherapy before irreversible cutaneous scarring occurs. Integrating metabolic therapies into HS treatment algorithms using metabolic and inflammatory biomarkers supports phenotype-driven care, offering a synergistic strategy to optimize cutaneous control, extend biologic drug survival, and improve cardiometabolic health in selected patients with HS.